GlassScriptPhysician profile
Jere Thompson
NPI 1366730558
$8,136.78
in general payments reported to CMS, 2019-2025
39 companies · $2,340 in 2025
The $2,340 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,383 · 2022: $1,260 · 2023: $1,339 · 2024: $1,814 · 2025: $2,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,382 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,382.33 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,289.72 | 2021-2025 | |
| Novo Nordisk INC | $892.56 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $785.21 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $667.10 | 2021-2025 | Trintellix |
| Amgen INC. | $547.39 | 2021-2024 | Repatha, Otezla, Aimovig |
| Astrazeneca Pharmaceuticals LP | $497.75 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $439.20 | 2021-2025 | |
| Ardelyx, INC. | $335.18 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $265.37 | 2023-2024 | Xifaxan |
| Revance Therapeutics, INC. | $216.95 | 2024 | Daxi, Daxxify |
| Axsome Therapeutics, INC. | $209.85 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $179.17 | 2021-2025 | |
| Astellas Pharma US INC | $177.50 | 2022-2024 | Veozah |
| Amarin Pharma, INC. | $175.34 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $160.70 | 2022-2023 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $129.35 | 2024-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.19 | 2021-2024 | Synjardy, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $96.74 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $91.60 | 2025 | Cobenfy |
| Alkermes, INC. | $89.70 | 2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.38 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $82.46 | 2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $71.93 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $61.37 | 2025 | Jornay Pm |
| Phathom Pharmaceuticals, INC. | $51.70 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $51.12 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lundbeck LLC | $50.40 | 2024-2025 | Vyepti |
| Corcept Therapeutics | $43.21 | 2024-2025 | Korlym |
| Idorsia Pharmaceuticals US INC | $34.77 | 2023 | Quviviq |
| Exact Sciences Corporation | $32.98 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $31.59 | 2025 | Fanapt |
| Tris Pharma INC | $28.43 | 2022 | |
| Antares Pharma, INC. | $23.99 | 2024 | Xyosted |
| Neurocrine Biosciences, INC. | $22.26 | 2025 | |
| Abbott Laboratories | $21.93 | 2023 | Freestyle Libre 3 |
| Insulet Corporation | $19.02 | 2025 | Omnipod |
| Biohaven Pharmaceuticals, INC. | $17.53 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.72 | 2021 | |
| Acella Pharmaceuticals, LLC | $14.42 | 2024 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jere Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.